Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.
Tivozanib 加 nivolumab 與 tivozanib 單藥治療在接受免疫檢查點抑制劑後的腎細胞癌患者中的比較:第 3 期 TiNivo-2 研究結果。
Lancet 2024-09-16
Adverse renal effects of check-point inhibitors (ICI) in cancer patients: Recommendations of the Onco-nephrology Working Group of the Spanish Society of Nephrology.
癌症患者中免疫檢查點抑制劑(ICI)的腎臟不良影響:西班牙腎臟學會腫瘤腎臟學工作組的建議。
Nefrologia (Engl Ed) 2024-01-31
Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens.
腎細胞癌中的免疫原性:將焦點轉向腫瘤特異性抗原的替代來源。
Nat Rev Nephrol 2024-01-23
Clear Cell Renal Cell Carcinoma: A Comprehensive in silico Study in Searching for Therapeutic Targets.
清除細胞腎細胞癌:全面的體外研究尋找治療靶點。
Kidney Blood Press Res 2024-04-12